18, 2025 /PRNewswire/ -- Today, Novo Nordisk announced the submission of a New Drug Application (NDA) to the U.S
It does not provide instructions for human or veterinary use, dosing, administration, reconstitution, compounding, or personal experimentation
(PubMed) Oliai Araghi S, Kiefte-de Jong JC, van Dijk SC, et al
Both belong to a new generation of injectable peptide-based therapies that work by targeting multiple hormonal pathways simultaneously, offering potentially greater metabolic benefits than earlier single-receptor agents
Lower risk of severe side effects : Compared to other weight loss medications, Mounjaro tends to have a favorable safety profile, with fewer reports of severe gastrointestinal side effects than some other injectable GLP-1-based drugs